Plasma Omega-3 Polyunsaturated Fatty Acids and Survival in Patients with Chronic Heart Failure and Major Depressive Disorder

Jiang, Wei; Oken, Harry A.; Fiuzat, Mona; Shaw, Linda K.; Martsberger, Carolyn; Kuchibhatla, Maragatha; Kaddurah‐Daouk, Rima; Steffens, David C.; Baillie, Rebecca; Cuffe, Michael S.; Krishnan, Ranga; O’Connor, Christopher M.

doi:10.1007/s12265-011-9325-8

Cited by 27 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Briefly, a total of 493 independent citations were identified after duplicate exclusion, of which 32 were retrieved for full-text review. Ten publications were excluded because the exposure or outcome was not relevant to the topic we studied; 11 reports were excluded because they investigated dietary/circulating n-3 LCPUFA among patients with certain diseases, such as type 2 diabetes2324, CHD25262728, heart failure2930, and kidney disease313233; further excluded was one publication34 which was an overlapping report of another35 with larger events. Finally, 10 publications13141516171819202122 including 11 independent prospective studies (2 cohorts were combined in one publication17) were included in this meta-analysis, involving 7 studies131415161718 on dietary n-3 LCPUFA and 4 studies19202122 on circulating EPA/DHA in relation to all-cause mortality risk.…”

Section: Resultsmentioning

confidence: 99%

N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis

Chen

Yang

Eggersdorfer³

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Prospective observational studies have shown inconsistent associations of dietary or circulating n-3 long-chain polyunsaturated fatty acids (LCPUFA) with risk of all-cause mortality. A meta-analysis was performed to evaluate the associations. Potentially eligible studies were identified by searching PubMed and EMBASE databases. The summary relative risks (RRs) with 95% confidence intervals (CIs) were calculated using the random-effects model. Eleven prospective studies involving 371 965 participants from general populations and 31 185 death events were included. The summary RR of all-cause mortality for high-versus-low n-3 LCPUFA intake was 0.91 (95% CI: 0.84–0.98). The summary RR for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) intake was 0.83 (95% CI: 0.75–0.92) and 0.81 (95% CI: 0.74–0.95), respectively. In the dose-response analysis, each 0.3 g/d increment in n-3 LCPUFA intake was associated with 6% lower risk of all-cause mortality (RR = 0.94, 95% CI: 0.89–0.99); and each 1% increment in the proportions of circulating EPA and DHA in total fatty acids in blood was associated with 20% (RR = 0.80, 95% CI: 0.65–0.98) and 21% (RR = 0.79, 95% CI: 0.63–0.99) decreased risk of all-cause mortality, respectively. Moderate to high heterogeneity was observed across our anlayses. Our findings suggest that both dietary and circulating LCPUFA are inversely associated with all-cause mortality.

show abstract

Section: Resultsmentioning

confidence: 99%

N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis

Chen

Yang

Eggersdorfer³

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Due to limited blood volume following the metabolomics and the lipidomics studies 33,34 , adequate blood sample volume suitable for this inflammatory biomarker study was only available for 157 of the 175 subjects. Two subjects were missing data for important covariates resulting in a final sample size of 155: 130 from the MDD groups (Mild: n = 48; Moderate: n =49; and Severe: n = 33) and 25 from the none-depressed group.…”

Section: Resultsmentioning

confidence: 99%

Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure

Xiong

Prybol

Boyle

et al. 2015

Psychosomatic Medicine

Self Cite

View full text Add to dashboard Cite

Background Major Depressive Disorder (MDD) and Chronic Heart Failure (CHF) have in common heightening states of inflammation, manifested by elevated inflammation markers such as C-reactive protein (CRP). This study compared inflammatory biomarker profiles in CHF patients with MDD to those without MDD. Methods The study recruited patients admitted to inpatient care for acute heart failure exacerbations, after psychiatric diagnostic interview. Patients with Beck Depression Inventory (BDI) scores < 10 and with no prior history of depression served as the non-depressed reference group (n = 25). MDD severity was defined as: Mild (BDI 10–15; n = 48); Moderate (BDI 16–23; n = 51); and Severe (BDI ≥ 24; n = 33). A Bio-Plex assay measured 18 inflammation markers. Ordinal logistic models were used to examine the association of MDD severity and biomarker levels. Results Adjusting for age, sex, statin use, BMI, LVEF, tobacco use, and NHYA class the MDD overall group variable was significantly associated with elevated interleukin (IL) −2 (p = .019), IL-4 (p = .020), IL-6 (p = .026),, interferon (INF)-γ (p = .010), monocyte chemoattractant protein (MCP-1) (p = .002), macrophage inflammatory protein (MIP-1β) (p = .003) and tumor necrosis factor (TNF)-α (p = .004). MDD severity subgroups had a greater probability of elevated IL-6, IL-8, IFN-γ, MCP-1, MIP-1β, and TNF-α compared to none-depressed group. The non-depressed group had greater probability of elevated IL-17 (p < 0.001) and IL-1β (p < 0.01). Conclusions MDD in CHF patients was associated with altered inflammation marker levels compared to CHF patients who had no depression. Whether effective depression treatment will normalize the altered inflammation marker levels requires further study.

show abstract

“…Depression remains poorly detected despite its prevalence and its association with increased mortality [173], as symptoms of depression can overlap with those of heart failure. Interestingly, some authors have suggested that low plasma omega-3 fatty acid is a factor for reduced survival in CHF patients with depression [174]. Vigilant survey with screening tools such as patient health questionnaire can aid detection of depression in CHF patients [175].…”

Section: Depressionmentioning

confidence: 99%

Management of Noncardiac Comorbidities in Chronic Heart Failure

Chong

Singh

Parry

et al. 2015

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SummaryPrevalence of heart failure is increasing, especially in the elderly population. Noncardiac comorbidities complicate heart failure care and are increasingly common in elderly patients with reduced or preserved ejection fraction heart failure, owing to prolongation of patient's lives by advances in chronic heart failure (CHF) management. Common comorbidities include respiratory disease, renal dysfunction, anemia, arthritis, obesity, diabetes mellitus, cognitive dysfunction, and depression. These conditions contribute to the progression of the disease and may alter the response to treatment, partly as polypharmacy is inevitable in these patients. Cardiologists and other physicians caring for patients with CHF need to be vigilant to comorbid conditions that complicate the care of these patients. There is now more guidance on management of noncardiac comorbidities in heart failure, and this article contains a comprehensive review of the most recent updates on management of noncardiac comorbidities in CHF.

show abstract

Plasma Omega-3 Polyunsaturated Fatty Acids and Survival in Patients with Chronic Heart Failure and Major Depressive Disorder

Cited by 27 publications

References 56 publications

N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis

N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis

Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure

Management of Noncardiac Comorbidities in Chronic Heart Failure

Contact Info

Product

Resources

About